12月24日 - ** 制药商Biohaven BHVN.N的股票在延时交易中下跌16%至9美元
** 该公司称其药物BHV-7000没有达到 (link)，主要目标是减轻重度抑郁症患者的抑郁症状。
** 该药物正处于概念验证的中期研究阶段
** BHVN 表示，公司不打算进行更多的精神科临床试验，以便在 2026 年将资源集中在免疫学、肥胖症和癫痫等关键优先领域。
** 截至上次收盘，股价年累计下跌 71
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.